{"id":"W4414167602","doi":"10.1002/ehf2.15393","title":"Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI","year":2025,"lang":"en","type":"article","venue":"ESC Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Canadian VIGOUR Centre; University of Alberta; University Health Network; Women's College Hospital","funders":"American Regent; Abbott Vascular; Esperion Therapeutics; Daiichi Sankyo Europe; Servier; Vifor Pharma; Universitair Medisch Centrum Groningen; University of Toronto; Bayer HealthCare; Sanofi; Abiomed; Horizon Therapeutics; Pfizer; York University; Moderna; Idorsia Pharmaceuticals; Impulse Dynamics; Novo Nordisk; MyoKardia; Norgine; Novavax; ZOLL Medical Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Boston Scientific Corporation; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Duke Clinical Research Institute; Astellas Pharma; Cytokinetics; HLS Therapeutics; GlaxoSmithKline; LivaNova; Heart and Stroke Foundation of Canada; Amgen; Patient-Centered Outcomes Research Institute","keywords":"Empagliflozin; Myocardial infarction; Diabetes mellitus; Heart failure; Kidney disease; Type 2 diabetes","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004209137,0.0002473262,0.0003790785,0.0001627762,0.00009181422,0.00008000006,0.00004304976,0.00008123709,0.0003489914],"category_scores_gemma":[0.00003814512,0.000164649,0.00007403553,0.0002271531,0.00009738603,0.0001912612,0.00006887424,0.0001492905,0.00006295749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001204459,"about_ca_system_score_gemma":0.0002899999,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003874033,"about_ca_topic_score_gemma":0.0001505977,"domain_scores_codex":[0.9988655,0.00004591573,0.0001623276,0.0003967218,0.0002320724,0.0002974992],"domain_scores_gemma":[0.9991441,0.0000383711,0.0000305408,0.0003671765,0.00004428866,0.0003754631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001038494,0.0002191707,0.9199945,0.0003174753,0.001245261,0.00004725852,0.0003291231,0.000002631956,0.001299308,0.00008881626,0.07306504,0.002352928],"study_design_scores_gemma":[0.004172942,0.0005667704,0.5500526,0.0008793447,0.001092199,7.510865e-7,0.00009920652,0.000140605,0.001057111,0.000119748,0.4415811,0.0002376193],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842005,0.001697145,0.0000276137,0.01223711,0.0001924429,0.0007963785,0.00003454667,0.0001346755,0.0006796275],"genre_scores_gemma":[0.9911156,0.0000483304,0.000635066,0.00379664,0.0003113433,0.0002171311,0.00015614,0.00002718545,0.00369251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3699419,"threshold_uncertainty_score":0.6714191,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004717815387064102,"score_gpt":0.2305960315706345,"score_spread":0.2258782161835704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}